 Polyvalent display libraries |
| I. General The present invention is directed to inter alia two related but self-sufficient ... |
|
| Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus |
| OF THE INVENTION A. Definitions Amino Acid Residue: An amino acid formed upon chemical digestion (... |
|
| Pharmaceutical and diagnostic business systems and methods |
| Improved business methods, devices, and systems for utilizing genetic information are provided. A... |
|
| Method of differential display of exposed mRNA by RT/PCR |
| We claim: 1. A method of comparing the presence or level of individual mRNA molecules in two or ... |
|
| Methods of screening for compounds that derepress or increase telomerase activity |
| We claim: 1. Method for screening for a telomerase derepression agent, the method comprising the ... |
|
| Oral vaccines |
| What is claimed is: 1. A protein conjugate comprising an immunogen covalently linked to a carrier ... |
|
| Method for identifying validated target and assay combinations for drug development |
| The invention relates to methods that couple the validation of a target (see Definitions) for drug ... |
|
|
Protease-activated receptor PAR4 (ZCHEMR2)
| Details |
Inventors: Xu, Wen-feng; Presnell, Scott R.; Yee, David P.; Foster, Donald C.;
Assignee: ZymoGenetics, Inc. (Seattle, WA) University of Washington (Seattle, WA)
Primary Examiner: Ulm; John
Assistant Examiner:
Attorney, Agent or Firm: Lewis; Michelle L. Jones; Phillip B. D.
The present invention relates to polynucleotide and polypeptide molecules for PAR4, a novel member of the protease-activated receptor family. The polypeptides, and polynucleotides encoding them, mediate biological responses and/or cellular signaling in response to proteases. Protease cleavage of PAR4 exposes a PAR4 extracellular amino terminal portion that serves as a ligand for the PAR4 receptor. PAR4 may be used as a target in drug screening, and further used to identify proteinaceous or non-proteinaceous PAR4 agonists and antagonists. The present invention also includes antibodies to the PAR4 polypeptides. |
|
DETAILED DESCRIPTION What is claimed is: 1.
An isolated polynucleotide molecule that encodes a polypeptide comprising amino acid residues 48 to 78 of SEQ ID NO:2.
2.
The isolated polynucleotide molecule of claim 1, wherein the polynucleotide molecule comprises nucleotides 317 to 409 of SEQ ID NO:1.
3.
A composition comprising the isolated polynucleotide molecule of claim 1.
4.
The isolated polynucleotide molecule of claim 1, wherein the polynucleotide molecule is a DNA molecule.
5.
A vector, comprising the isolated polynucleotide molecule of claim 1.
6.
The isolated polynucleotide molecule of claim 1, wherein the polynucleotide molecule encodes a polypeptide comprising amino acid residues 18 to 78 of SEQ ID NO:2.
7.
The isolated polynucleotide molecule of claim 6, wherein the polynucleotide molecule comprises nucleotides 227 to 409 of SEQ ID NO:1.
8.
The isolated polynucleotide molecule of claim 1, wherein the polynucleotide molecule encodes a polypeptide comprising amino acid residues 18 to 385 of SE ID NO:2.
9.
The isolated polynucleotide molecule of claim 8, wherein the polynucleotide molecule comprises nucleotides 227 to 1330 of SEQ ID NO:1.
10.
The isolated polynucleotide molecule of claim 1, wherein the polynucleotide molecule encodes a polypeptide comprising amino acid residues 1 to 385 of SEQ ID NO:2.
11.
The isolated polynucleotide molecule of claim 10, wherein the polynucleotide molecule comprises nucleotides 176 to 1330 of SEQ ID NO:1.
12.
An isolated polynucleotide molecule that encodes the amino acid sequence of SEQ ID NO:7.
13.
An isolated polynucleotide molecule comprising a nucleotide sequence that is complementary to the nucleotide sequence of SEQ ID NO:1.
14.
An expression vector, comprising a polynucleotide molecule that encodes a polypeptide comprising amino acid residues 18 to 78 of SEQ ID NO:2, a transcription promoter, and a transcription terminator, wherein the promoter is operably linked with the polynucleotide molecule, and wherein the polynucleotide molecule is operably linked with the transcription terminator
|
| Related patents |
|
|
Systemic drug delivery compositions comprising a polycationi substance
I claim: 1. A method of systemically delivering a pharmaceutically effective amount of a pharmacologically active compound to a mammal comprising: administering to a ...
|
|
|
Nucleic acid-containing composition, its preparation and use
We claim: 1. A composition comprising a deoxyribonucleic acid and a cationic oligopeptide that forms secondary structures, wherein the oligopeptide corresponds to the ...
|
|
|
Peptide-enhanced cationic lipid transfections
OF THE INVENTION The present invention provides improved methods for transfecting eukaryotic cells with nucleic acids by employing peptides or modified peptides in ...
|
|
|
Controlled release formulations coated with aqueous dispersions of acrylic polymers
It is therefore an object of the present invention to provide a controlled release formulation of a substrate comprising an active agent, e.g. a therapeutically active ...
|
|
|
Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides
What is claimed is: 1. A compound having the formula I: ##STR5## wherein, R.sub.1 is OH, O--R.sub.3, C--R.sub.3, halo, NHR.sub.4, ONHR.sub.5 or ON.dbd.R.sub.6, wherein R....
|
|
|
Substituted indazole-O-glucosides
OF THE INVENTION All diabetics, regardless of their genetic and environmental backgrounds, have in common an apparent lack of insulin or inadequate insulin function. B...
|
|
|
Production in Escherichia coli of extracellular Serratia spp. hydrolases
We claim: 1. A method of producing an extracellular hydrolytic Serratia spp. enzyme selected from the group consisting of exocellular nuclease, exocellular phospholipase ...
|
|
|
Modular assembly of antibody genes, antibodies prepared thereby and use
What is claimed is: 1. A polynucleotide molecule encoding an immunoglobulin fragment, said immunoglobulin fragment comprising a first DNA sequence encoding a first ...
|
|
|
Cytoplasmic bacteriophage display system
The present invention relates, in one aspect, to a display vector comprising DNA encoding a portion of a structural protein from a cytoplasmic bacteriophage, joined ...
|
|
|
Diagnosis of alzheimer disease stage by mononuclear cell cytokine secretions
AND ADVANTAGES According to the present invention, a method of diagnosing and determining the disease stage or severity of a degenerative disease of the central nervous ...
|
|
|
Gene Therapy 
